...
机译:SLC28A3,SLC29A1和RRM1的遗传多态性预测患有Gemcitabine Plus紫杉醇化疗的转移性乳腺癌患者的临床结果
Department of Laboratory Medicine and Genetics Samsung Medical Center Sungkyunkwan University;
Department of Internal Medicine Seoul National University Hospital Seoul National University;
Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine 50;
Biostatistics Team Samsung Biomedical Research Institute Sungkyunkwan University School of;
Biostatistics Team Samsung Biomedical Research Institute Sungkyunkwan University School of;
Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine 50;
Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine 50;
Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine 50;
Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine 50;
Breast cancer; Gemcitabine; Paclitaxel; Pharmacogenomics;
机译:SLC28A3,SLC29A1和RRM1的遗传多态性预测接受吉西他滨联合紫杉醇化疗的转移性乳腺癌患者的临床结局
机译:RRM1 -37A> C基因多态性与吉西他滨类化学疗法治疗结直肠癌患者的临床结局相关性。
机译:转移性结直肠癌患者西妥昔单抗联合伊立替康化疗后,FcγRIIa和FcγRIIIa的遗传多态性不能预测临床结果
机译:乳腺癌中疗药物相关酶的遗传多态性及其临床意义
机译:吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
机译:周围神经病变的早期发作可能是接受含紫杉醇化疗的转移性乳腺癌患者治疗失败时间的有力预测指标
机译:周围神经病变的早期发作可能是接受含有紫杉醇化疗的转移性乳腺癌患者治疗失败时间的有力预测因子。